Warning letter
SCA Pharmaceuticals, LLC: warning letter of Sep 14, 2026
FDA warning letter 724202 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 724202 |
|---|---|
| Company | SCA Pharmaceuticals, LLC |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Sep 14, 2026 |
| Posted date | Oct 13, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 200.10(b), 211.22(d), 211.42(c)(10)(iii), 211.113(b), 211.160(b), 211.192, 210.1(b) |
| Inspection city | Little Rock |
| Inspection ZIP | 72205 |
| Inspection start date | Oct 20, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: